GlobeNewswire Inc | Jan 4, 2022 07:30AM EST

January 04, 2022

CORAL GABLES, Fla., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.(Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced thatPatrick J. McEnany, Catalyst's Chairman and Chief Executive Officer andSteven Miller, Ph.D., Chief Scientific Officer/COO, will participate in two upcoming investor conferences:

Conference: Solebury Trout 1x1 Management Access Event 2022Format: One-on-one virtual meetingsDates: January 10-20, 2022Register: Solebury Trout 1x1 Management Access Event 2022 Solebury Trout Access Conference: H.C. Wainwright Global BIOCONNECT Virtual ConferenceFormat: On-demand recorded corporate presentationDates: January 10-13, 2022Webcast: https://journey.ct.events/view/2cf56b15-2bbe-4efc-bca5-5215071116a8

Catalyst's pre-recorded presentation will be available on the H.C. Wainwright conference website for viewing on-demand beginningMonday, January 10, 2022, at7:00 AM ESTand will also be available on the Investor section of thecompany's websitepromptly following the scheduled presentation time.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticalsis a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE(amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by theU.S. Food & Drug Administration("FDA"), and FIRDAPSE is commercially available inthe United Statesas a treatment for adults with LEMS. Further,Canada'snational healthcare regulatory agency,Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients inCanadawith LEMS.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2020 and its other filings with theU.S. Securities and Exchange Commission(SEC), could adversely affect Catalyst. Copies of Catalyst's filings with theSECare available from theSEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.

Investor ContactMary ColemanCatalyst Pharmaceuticals, Inc.mcoleman@catalystpharma.com

Media ContactDavid SchullRusso Partners(858) 717-2310david.schull@russopartnersllc.com